Search

Your search keyword '"Petrovics, Gyorgy"' showing total 644 results
Start Over Author "Petrovics, Gyorgy"
644 results on '"Petrovics, Gyorgy"'

1. Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression

Author

Diossy, Miklos, Tisza, Viktoria, Li, Hua, Sahgal, Pranshu, Zhou, Jia, Sztupinszki, Zsofia, Young, Denise, Nousome, Darryl, Kuo, Claire, Jiang, Jiji, Chen, Yongmei, Ebner, Reinhard, Sesterhenn, Isabell A., Moncur, Joel T., Chesnut, Gregory T., Petrovics, Gyorgy, Klus, Gregory T., Valcz, Gabor, Nuzzo, Pier Vitale, Ribli, Dezso, Börcsök, Judit, Prosz, Aurel, Krzystanek, Marcin, Ried, Thomas, Szuts, David, Rizwan, Kinza, Kaochar, Salma, Pathania, Shailja, D’Andrea, Alan D., Csabai, Istvan, Srivastava, Shiv, Freedman, Matthew L., Dobi, Albert, Spisak, Sandor, and Szallasi, Zoltan

Published
2024
Full Text
View/download PDF

2. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score

Author

Huynh-Le, Minh-Phuong, Karunamuni, Roshan, Fan, Chun Chieh, Asona, Lui, Thompson, Wesley K, Martinez, Maria Elena, Eeles, Rosalind A, Kote-Jarai, Zsofia, Muir, Kenneth R, Lophatananon, Artitaya, Schleutker, Johanna, Pashayan, Nora, Batra, Jyotsna, Grönberg, Henrik, Neal, David E, Nordestgaard, Børge G, Tangen, Catherine M, MacInnis, Robert J, Wolk, Alicja, Albanes, Demetrius, Haiman, Christopher A, Travis, Ruth C, Blot, William J, Stanford, Janet L, Mucci, Lorelei A, West, Catharine ML, Nielsen, Sune F, Kibel, Adam S, Cussenot, Olivier, Berndt, Sonja I, Koutros, Stella, Sørensen, Karina Dalsgaard, Cybulski, Cezary, Grindedal, Eli Marie, Menegaux, Florence, Park, Jong Y, Ingles, Sue A, Maier, Christiane, Hamilton, Robert J, Rosenstein, Barry S, Lu, Yong-Jie, Watya, Stephen, Vega, Ana, Kogevinas, Manolis, Wiklund, Fredrik, Penney, Kathryn L, Huff, Chad D, Teixeira, Manuel R, Multigner, Luc, Leach, Robin J, Brenner, Hermann, John, Esther M, Kaneva, Radka, Logothetis, Christopher J, Neuhausen, Susan L, De Ruyck, Kim, Ost, Piet, Razack, Azad, Newcomb, Lisa F, Fowke, Jay H, Gamulin, Marija, Abraham, Aswin, Claessens, Frank, Castelao, Jose Esteban, Townsend, Paul A, Crawford, Dana C, Petrovics, Gyorgy, van Schaik, Ron HN, Parent, Marie-Élise, Hu, Jennifer J, Zheng, Wei, Mills, Ian G, Andreassen, Ole A, Dale, Anders M, and Seibert, Tyler M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prevention, Cancer, Health Disparities, Prostate Cancer, Aging, Genetics, Precision Medicine, Urologic Diseases, Minority Health, Good Health and Well Being, Male, Humans, Prostate-Specific Antigen, Prostatic Neoplasms, Early Detection of Cancer, Polymorphism, Single Nucleotide, Risk Factors, Risk Assessment, Genetic Predisposition to Disease, UKGPCS collaborators, APCB, NC-LA PCaP Investigators, IMPACT Study Steering Committee and Collaborators, Canary PASS Investigators, Profile Study Steering Committee, PRACTICAL Consortium, Urology & Nephrology, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundProstate cancer risk stratification using single-nucleotide polymorphisms (SNPs) demonstrates considerable promise in men of European, Asian, and African genetic ancestries, but there is still need for increased accuracy. We evaluated whether including additional SNPs in a prostate cancer polygenic hazard score (PHS) would improve associations with clinically significant prostate cancer in multi-ancestry datasets.MethodsIn total, 299 SNPs previously associated with prostate cancer were evaluated for inclusion in a new PHS, using a LASSO-regularized Cox proportional hazards model in a training dataset of 72,181 men from the PRACTICAL Consortium. The PHS model was evaluated in four testing datasets: African ancestry, Asian ancestry, and two of European Ancestry-the Cohort of Swedish Men (COSM) and the ProtecT study. Hazard ratios (HRs) were estimated to compare men with high versus low PHS for association with clinically significant, with any, and with fatal prostate cancer. The impact of genetic risk stratification on the positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was also measured.ResultsThe final model (PHS290) had 290 SNPs with non-zero coefficients. Comparing, for example, the highest and lowest quintiles of PHS290, the hazard ratios (HRs) for clinically significant prostate cancer were 13.73 [95% CI: 12.43-15.16] in ProtecT, 7.07 [6.58-7.60] in African ancestry, 10.31 [9.58-11.11] in Asian ancestry, and 11.18 [10.34-12.09] in COSM. Similar results were seen for association with any and fatal prostate cancer. Without PHS stratification, the PPV of PSA testing for clinically significant prostate cancer in ProtecT was 0.12 (0.11-0.14). For the top 20% and top 5% of PHS290, the PPV of PSA testing was 0.19 (0.15-0.22) and 0.26 (0.19-0.33), respectively.ConclusionsWe demonstrate better genetic risk stratification for clinically significant prostate cancer than prior versions of PHS in multi-ancestry datasets. This is promising for implementing precision-medicine approaches to prostate cancer screening decisions in diverse populations.

Published
2022

3. A selective CutMix approach improves generalizability of deep learning-based grading and risk assessment of prostate cancer

Author

Patkar, Sushant, Harmon, Stephanie, Sesterhenn, Isabell, Lis, Rosina, Merino, Maria, Young, Denise, Brown, G. Thomas, Greenfield, Kimberly M., McGeeney, John D., Elsamanoudi, Sally, Tan, Shyh-Han, Schafer, Cara, Jiang, Jiji, Petrovics, Gyorgy, Dobi, Albert, Rentas, Francisco J., Pinto, Peter A., Chesnut, Gregory T., Choyke, Peter, Turkbey, Baris, and Moncur, Joel T.

Published
2024
Full Text
View/download PDF

4. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

Author

Wang, Anqi, Shen, Jiayi, Rodriguez, Alex A., Saunders, Edward J., Chen, Fei, Janivara, Rohini, Darst, Burcu F., Sheng, Xin, Xu, Yili, Chou, Alisha J., Benlloch, Sara, Dadaev, Tokhir, Brook, Mark N., Plym, Anna, Sahimi, Ali, Hoffman, Thomas J., Takahashi, Atushi, Matsuda, Koichi, Momozawa, Yukihide, Fujita, Masashi, Laisk, Triin, Figuerêdo, Jéssica, Muir, Kenneth, Ito, Shuji, Liu, Xiaoxi, Uchio, Yuji, Kubo, Michiaki, Kamatani, Yoichiro, Lophatananon, Artitaya, Wan, Peggy, Andrews, Caroline, Lori, Adriana, Choudhury, Parichoy P., Schleutker, Johanna, Tammela, Teuvo L. J., Sipeky, Csilla, Auvinen, Anssi, Giles, Graham G., Southey, Melissa C., MacInnis, Robert J., Cybulski, Cezary, Wokolorczyk, Dominika, Lubinski, Jan, Rentsch, Christopher T., Cho, Kelly, Mcmahon, Benjamin H., Neal, David E., Donovan, Jenny L., Hamdy, Freddie C., Martin, Richard M., Nordestgaard, Borge G., Nielsen, Sune F., Weischer, Maren, Bojesen, Stig E., Røder, Andreas, Stroomberg, Hein V., Batra, Jyotsna, Chambers, Suzanne, Horvath, Lisa, Clements, Judith A., Tilly, Wayne, Risbridger, Gail P., Gronberg, Henrik, Aly, Markus, Szulkin, Robert, Eklund, Martin, Nordstrom, Tobias, Pashayan, Nora, Dunning, Alison M., Ghoussaini, Maya, Travis, Ruth C., Key, Tim J., Riboli, Elio, Park, Jong Y., Sellers, Thomas A., Lin, Hui-Yi, Albanes, Demetrius, Weinstein, Stephanie, Cook, Michael B., Mucci, Lorelei A., Giovannucci, Edward, Lindstrom, Sara, Kraft, Peter, Hunter, David J., Penney, Kathryn L., Turman, Constance, Tangen, Catherine M., Goodman, Phyllis J., Thompson, Jr., Ian M., Hamilton, Robert J., Fleshner, Neil E., Finelli, Antonio, Parent, Marie-Élise, Stanford, Janet L., Ostrander, Elaine A., Koutros, Stella, Beane Freeman, Laura E., Stampfer, Meir, Wolk, Alicja, Håkansson, Niclas, Andriole, Gerald L., Hoover, Robert N., Machiela, Mitchell J., Sørensen, Karina Dalsgaard, Borre, Michael, Blot, William J., Zheng, Wei, Yeboah, Edward D., Mensah, James E., Lu, Yong-Jie, Zhang, Hong-Wei, Feng, Ninghan, Mao, Xueying, Wu, Yudong, Zhao, Shan-Chao, Sun, Zan, Thibodeau, Stephen N., McDonnell, Shannon K., Schaid, Daniel J., West, Catharine M. L., Barnett, Gill, Maier, Christiane, Schnoeller, Thomas, Luedeke, Manuel, Kibel, Adam S., Drake, Bettina F., Cussenot, Olivier, Cancel-Tassin, Geraldine, Menegaux, Florence, Truong, Thérèse, Koudou, Yves Akoli, John, Esther M., Grindedal, Eli Marie, Maehle, Lovise, Khaw, Kay-Tee, Ingles, Sue A., Stern, Mariana C., Vega, Ana, Gómez-Caamaño, Antonio, Fachal, Laura, Rosenstein, Barry S., Kerns, Sarah L., Ostrer, Harry, Teixeira, Manuel R., Paulo, Paula, Brandão, Andreia, Watya, Stephen, Lubwama, Alexander, Bensen, Jeannette T., Butler, Ebonee N., Mohler, James L., Taylor, Jack A., Kogevinas, Manolis, Dierssen-Sotos, Trinidad, Castaño-Vinyals, Gemma, Cannon-Albright, Lisa, Teerlink, Craig C., Huff, Chad D., Pilie, Patrick, Yu, Yao, Bohlender, Ryan J., Gu, Jian, Strom, Sara S., Multigner, Luc, Blanchet, Pascal, Brureau, Laurent, Kaneva, Radka, Slavov, Chavdar, Mitev, Vanio, Leach, Robin J., Brenner, Hermann, Chen, Xuechen, Holleczek, Bernd, Schöttker, Ben, Klein, Eric A., Hsing, Ann W., Kittles, Rick A., Murphy, Adam B., Logothetis, Christopher J., Kim, Jeri, Neuhausen, Susan L., Steele, Linda, Ding, Yuan Chun, Isaacs, William B., Nemesure, Barbara, Hennis, Anselm J. M., Carpten, John, Pandha, Hardev, Michael, Agnieszka, De Ruyck, Kim, De Meerleer, Gert, Ost, Piet, Xu, Jianfeng, Razack, Azad, Lim, Jasmine, Teo, Soo-Hwang, Newcomb, Lisa F., Lin, Daniel W., Fowke, Jay H., Neslund-Dudas, Christine M., Rybicki, Benjamin A., Gamulin, Marija, Lessel, Davor, Kulis, Tomislav, Usmani, Nawaid, Abraham, Aswin, Singhal, Sandeep, Parliament, Matthew, Claessens, Frank, Joniau, Steven, Van den Broeck, Thomas, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Martinez, Maria Elena, Larkin, Samantha, Townsend, Paul A., Aukim-Hastie, Claire, Bush, William S., Aldrich, Melinda C., Crawford, Dana C., Srivastava, Shiv, Cullen, Jennifer, Petrovics, Gyorgy, Casey, Graham, Wang, Ying, Tettey, Yao, Lachance, Joseph, Tang, Wei, Biritwum, Richard B., Adjei, Andrew A., Tay, Evelyn, Truelove, Ann, Niwa, Shelley, Yamoah, Kosj, Govindasami, Koveela, Chokkalingam, Anand P., Keaton, Jacob M., Hellwege, Jacklyn N., Clark, Peter E., Jalloh, Mohamed, Gueye, Serigne M., Niang, Lamine, Ogunbiyi, Olufemi, Shittu, Olayiwola, Amodu, Olukemi, Adebiyi, Akindele O., Aisuodionoe-Shadrach, Oseremen I., Ajibola, Hafees O., Jamda, Mustapha A., Oluwole, Olabode P., Nwegbu, Maxwell, Adusei, Ben, Mante, Sunny, Darkwa-Abrahams, Afua, Diop, Halimatou, Gundell, Susan M., Roobol, Monique J., Jenster, Guido, van Schaik, Ron H. N., Hu, Jennifer J., Sanderson, Maureen, Kachuri, Linda, Varma, Rohit, McKean-Cowdin, Roberta, Torres, Mina, Preuss, Michael H., Loos, Ruth J. F., Zawistowski, Matthew, Zöllner, Sebastian, Lu, Zeyun, Van Den Eeden, Stephen K., Easton, Douglas F., Ambs, Stefan, Edwards, Todd L., Mägi, Reedik, Rebbeck, Timothy R., Fritsche, Lars, Chanock, Stephen J., Berndt, Sonja I., Wiklund, Fredrik, Nakagawa, Hidewaki, Witte, John S., Gaziano, J. Michael, Justice, Amy C., Mancuso, Nick, Terao, Chikashi, Eeles, Rosalind A., Kote-Jarai, Zsofia, Madduri, Ravi K., Conti, David V., and Haiman, Christopher A.

Published
2023
Full Text
View/download PDF

5. Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24

Author

Karunamuni, Roshan A, Huynh-Le, Minh-Phuong, Fan, Chun C, Thompson, Wesley, Lui, Asona, Martinez, Maria Elena, Rose, Brent S, Mahal, Brandon, Eeles, Rosalind A, Kote-Jarai, Zsofia, Muir, Kenneth, Lophatananon, Artitaya, Tangen, Catherine M, Goodman, Phyllis J, Thompson, Ian M, Blot, William J, Zheng, Wei, Kibel, Adam S, Drake, Bettina F, Cussenot, Olivier, Cancel-Tassin, Géraldine, Menegaux, Florence, Truong, Thérèse, Park, Jong Y, Lin, Hui-Yi, Taylor, Jack A, Bensen, Jeannette T, Mohler, James L, Fontham, Elizabeth TH, Multigner, Luc, Blanchet, Pascal, Brureau, Laurent, Romana, Marc, Leach, Robin J, John, Esther M, Fowke, Jay H, Bush, William S, Aldrich, Melinda C, Crawford, Dana C, Cullen, Jennifer, Petrovics, Gyorgy, Parent, Marie-Élise, Hu, Jennifer J, Sanderson, Maureen, Mills, Ian G, Andreassen, Ole A, Dale, Anders M, and Seibert, Tyler M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Genetics, Black People, Case-Control Studies, Chromosomes, Human, Pair 8, Genetic Predisposition to Disease, Humans, Male, Multifactorial Inheritance, Polymorphism, Single Nucleotide, Prostatic Neoplasms, Risk Assessment, White People, UKGPCS Collaborators, PRACTICAL Consortium, Urology & Nephrology, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundWe previously developed an African-ancestry-specific polygenic hazard score (PHS46+African) that substantially improved prostate cancer risk stratification in men with African ancestry. The model consists of 46 SNPs identified in Europeans and 3 SNPs from 8q24 shown to improve model performance in Africans. Herein, we used principal component (PC) analysis to uncover subpopulations of men with African ancestry for whom the utility of PHS46+African may differ.Materials and methodsGenotypic data were obtained from the PRACTICAL consortium for 6253 men with African genetic ancestry. Genetic variation in a window spanning 3 African-specific 8q24 SNPs was estimated using 93 PCs. A Cox proportional hazards framework was used to identify the pair of PCs most strongly associated with the performance of PHS46+African. A calibration factor (CF) was formulated using Cox coefficients to quantify the extent to which the performance of PHS46+African varies with PC.ResultsCF of PHS46+African was strongly associated with the first and twentieth PCs. Predicted CF ranged from 0.41 to 2.94, suggesting that PHS46+African may be up to 7 times more beneficial to some African men than others. The explained relative risk for PHS46+African varied from 3.6% to 9.9% for individuals with low and high CF values, respectively. By cross-referencing our data set with 1000 Genomes, we identified significant associations between continental and calibration groupings.ConclusionWe identified PCs within 8q24 that were strongly associated with the performance of PHS46+African. Further research to improve the clinical utility of polygenic risk scores (or models) is needed to improve health outcomes for men of African ancestry.

Published
2022

6. Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24.

Author

Karunamuni, Roshan A, Huynh-Le, Minh-Phuong, Fan, Chun C, Thompson, Wesley, Lui, Asona, Martinez, Maria Elena, Rose, Brent S, Mahal, Brandon, Eeles, Rosalind A, Kote-Jarai, Zsofia, Muir, Kenneth, Lophatananon, Artitaya, UKGPCS Collaborators, Tangen, Catherine M, Goodman, Phyllis J, Thompson, Ian M, Blot, William J, Zheng, Wei, Kibel, Adam S, Drake, Bettina F, Cussenot, Olivier, Cancel-Tassin, Géraldine, Menegaux, Florence, Truong, Thérèse, Park, Jong Y, Lin, Hui-Yi, Taylor, Jack A, Bensen, Jeannette T, Mohler, James L, Fontham, Elizabeth TH, Multigner, Luc, Blanchet, Pascal, Brureau, Laurent, Romana, Marc, Leach, Robin J, John, Esther M, Fowke, Jay H, Bush, William S, Aldrich, Melinda C, Crawford, Dana C, Cullen, Jennifer, Petrovics, Gyorgy, Parent, Marie-Élise, Hu, Jennifer J, Sanderson, Maureen, PRACTICAL Consortium, Mills, Ian G, Andreassen, Ole A, Dale, Anders M, and Seibert, Tyler M

Subjects
UKGPCS Collaborators, PRACTICAL Consortium, Urologic Diseases, Prevention, Genetics, Prostate Cancer, Cancer, Urology & Nephrology, Oncology and Carcinogenesis
Abstract

BackgroundWe previously developed an African-ancestry-specific polygenic hazard score (PHS46+African) that substantially improved prostate cancer risk stratification in men with African ancestry. The model consists of 46 SNPs identified in Europeans and 3 SNPs from 8q24 shown to improve model performance in Africans. Herein, we used principal component (PC) analysis to uncover subpopulations of men with African ancestry for whom the utility of PHS46+African may differ.Materials and methodsGenotypic data were obtained from the PRACTICAL consortium for 6253 men with African genetic ancestry. Genetic variation in a window spanning 3 African-specific 8q24 SNPs was estimated using 93 PCs. A Cox proportional hazards framework was used to identify the pair of PCs most strongly associated with the performance of PHS46+African. A calibration factor (CF) was formulated using Cox coefficients to quantify the extent to which the performance of PHS46+African varies with PC.ResultsCF of PHS46+African was strongly associated with the first and twentieth PCs. Predicted CF ranged from 0.41 to 2.94, suggesting that PHS46+African may be up to 7 times more beneficial to some African men than others. The explained relative risk for PHS46+African varied from 3.6% to 9.9% for individuals with low and high CF values, respectively. By cross-referencing our data set with 1000 Genomes, we identified significant associations between continental and calibration groupings.ConclusionWe identified PCs within 8q24 that were strongly associated with the performance of PHS46+African. Further research to improve the clinical utility of polygenic risk scores (or models) is needed to improve health outcomes for men of African ancestry.

Published
2021

7. African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer.

Author

Karunamuni, Roshan A, Huynh-Le, Minh-Phuong, Fan, Chun C, Thompson, Wesley, Eeles, Rosalind A, Kote-Jarai, Zsofia, Muir, Kenneth, UKGPCS Collaborators, Lophatananon, Artitaya, Tangen, Catherine M, Goodman, Phyllis J, Thompson, Ian M, Blot, William J, Zheng, Wei, Kibel, Adam S, Drake, Bettina F, Cussenot, Olivier, Cancel-Tassin, Géraldine, Menegaux, Florence, Truong, Thérèse, Park, Jong Y, Lin, Hui-Yi, Bensen, Jeannette T, Fontham, Elizabeth TH, Mohler, James L, Taylor, Jack A, Multigner, Luc, Blanchet, Pascal, Brureau, Laurent, Romana, Marc, Leach, Robin J, John, Esther M, Fowke, Jay, Bush, William S, Aldrich, Melinda, Crawford, Dana C, Srivastava, Shiv, Cullen, Jennifer C, Petrovics, Gyorgy, Parent, Marie-Élise, Hu, Jennifer J, Sanderson, Maureen, Mills, Ian G, Andreassen, Ole A, Dale, Anders M, Seibert, Tyler M, and PRACTICAL Consortium

Subjects
UKGPCS Collaborators, PRACTICAL Consortium, Humans, Prostatic Neoplasms, Genetic Predisposition to Disease, Proportional Hazards Models, Case-Control Studies, Age Factors, Multifactorial Inheritance, Polymorphism, Single Nucleotide, Models, Genetic, Middle Aged, African Continental Ancestry Group, Male, Genotyping Techniques, African, genome wide association study, genomics, genotypic ancestry, health disparities, polygenic risk, prostate cancer, Aging, Genetics, Urologic Diseases, Cancer, Prostate Cancer, Prevention, Oncology & Carcinogenesis, Oncology and Carcinogenesis
Abstract

Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our model developed in Europeans (PHS46) showed reduced performance in men with African genetic ancestry. We used a cross-validated search to identify single nucleotide polymorphisms (SNPs) that might improve performance in this population. Anonymized genotypic data were obtained from the PRACTICAL consortium for 6253 men with African genetic ancestry. Ten iterations of a 10-fold cross-validation search were conducted to select SNPs that would be included in the final PHS46+African model. The coefficients of PHS46+African were estimated in a Cox proportional hazards framework using age at diagnosis as the dependent variable and PHS46, and selected SNPs as predictors. The performance of PHS46 and PHS46+African was compared using the same cross-validated approach. Three SNPs (rs76229939, rs74421890 and rs5013678) were selected for inclusion in PHS46+African. All three SNPs are located on chromosome 8q24. PHS46+African showed substantial improvements in all performance metrics measured, including a 75% increase in the relative hazard of those in the upper 20% compared to the bottom 20% (2.47-4.34) and a 20% reduction in the relative hazard of those in the bottom 20% compared to the middle 40% (0.65-0.53). In conclusion, we identified three SNPs that substantially improved the association of PHS46 with age at diagnosis of prostate cancer in men with African genetic ancestry to levels comparable to Europeans.

Published
2021

8. Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry

Author

Chen, Fei, Madduri, Ravi K., Rodriguez, Alex A., Darst, Burcu F., Chou, Alisha, Sheng, Xin, Wang, Anqi, Shen, Jiayi, Saunders, Edward J., Rhie, Suhn K., Bensen, Jeannette T., Ingles, Sue A., Kittles, Rick A., Strom, Sara S., Rybicki, Benjamin A., Nemesure, Barbara, Isaacs, William B., Stanford, Janet L., Zheng, Wei, Sanderson, Maureen, John, Esther M., Park, Jong Y., Xu, Jianfeng, Wang, Ying, Berndt, Sonja I., Huff, Chad D., Yeboah, Edward D., Tettey, Yao, Lachance, Joseph, Tang, Wei, Rentsch, Christopher T., Cho, Kelly, Mcmahon, Benjamin H., Biritwum, Richard B., Adjei, Andrew A., Tay, Evelyn, Truelove, Ann, Niwa, Shelley, Sellers, Thomas A., Yamoah, Kosj, Murphy, Adam B., Crawford, Dana C., Patel, Alpa V., Bush, William S., Aldrich, Melinda C., Cussenot, Olivier, Petrovics, Gyorgy, Cullen, Jennifer, Neslund-Dudas, Christine M., Stern, Mariana C., Kote-Jarai, Zsofia, Govindasami, Koveela, Cook, Michael B., Chokkalingam, Anand P., Hsing, Ann W., Goodman, Phyllis J., Hoffmann, Thomas J., Drake, Bettina F., Hu, Jennifer J., Keaton, Jacob M., Hellwege, Jacklyn N., Clark, Peter E., Jalloh, Mohamed, Gueye, Serigne M., Niang, Lamine, Ogunbiyi, Olufemi, Idowu, Michael O., Popoola, Olufemi, Adebiyi, Akindele O., Aisuodionoe-Shadrach, Oseremen I., Ajibola, Hafees O., Jamda, Mustapha A., Oluwole, Olabode P., Nwegbu, Maxwell, Adusei, Ben, Mante, Sunny, Darkwa-Abrahams, Afua, Mensah, James E., Diop, Halimatou, Van Den Eeden, Stephen K., Blanchet, Pascal, Fowke, Jay H., Casey, Graham, Hennis, Anselm J., Lubwama, Alexander, Thompson, Ian M., Jr., Leach, Robin, Easton, Douglas F., Preuss, Michael H., Loos, Ruth J., Gundell, Susan M., Wan, Peggy, Mohler, James L., Fontham, Elizabeth T., Smith, Gary J., Taylor, Jack A., Srivastava, Shiv, Eeles, Rosaline A., Carpten, John D., Kibel, Adam S., Multigner, Luc, Parent, Marie-Élise, Menegaux, Florence, Cancel-Tassin, Geraldine, Klein, Eric A., Andrews, Caroline, Rebbeck, Timothy R., Brureau, Laurent, Ambs, Stefan, Edwards, Todd L., Watya, Stephen, Chanock, Stephen J., Witte, John S., Blot, William J., Michael Gaziano, J., Justice, Amy C., Conti, David V., and Haiman, Christopher A.

Published
2023
Full Text
View/download PDF

10. Study about Predominance of ERG-Negative High-Grade Prostate Cancers in African American Men

Author

Farrell, James, primary, Yetter, Gavin, additional, Kohaar, Indu, additional, Young, Denise, additional, Chen, Yongmei, additional, Cullen, Jennifer, additional, Rosner, Inger L., additional, Kagan, Jacob, additional, Srivastava, Sudhir, additional, McLeod, David G., additional, Sesterhenn, Isabell A., additional, Srivastava, Shiv, additional, and Petrovics, Gyorgy, additional

Published
2022
Full Text
View/download PDF

11. A Review of Limbic System-Associated Membrane Protein in Tumorigenesis.

Author

Sinopole, Kayleigh Wittmann, Babcock, Kevin, Dobi, Albert, and Petrovics, Gyorgy

Subjects
OVARIAN epithelial cancer, SECOND messengers (Biochemistry), RENAL cell carcinoma, LIMBIC system, TUMOR suppressor proteins
Abstract

Purpose of Review: This review aims to describe the role of limbic system-associated membrane protein (LSAMP) in normal- and pathophysiology, and its potential implications in oncogenesis. We have summarized research articles reporting the role of LSAMP in the development of a variety of malignancies, such as clear cell renal cell carcinoma, prostatic adenocarcinoma, lung adenocarcinoma, osteosarcoma, neuroblastoma, acute myeloid leukemia, and epithelial ovarian cancer. We also examine the current understanding of how defects in LSAMP gene function may contribute to oncogenesis. Finally, this review discusses the implications of future LSAMP research and clinical applications. Recent Findings: LSAMP has been originally described as a surface adhesion glycoprotein expressed on cortical and subcortical neuronal somas and dendrites during the development of the limbic system. It is categorized as part of the IgLON immunoglobulin superfamily of cell-adhesion molecules and is involved in regulating neurite outgrowth and neural synapse generation. LSAMP is both aberrantly expressed and implicated in the development of neuropsychiatric disorders due to its role in the formation of specific neuronal connections within the brain. Additionally, LSAMP has been shown to support brain plasticity via the formation of neuronal synapses and is involved in modulating the hypothalamus in anxiogenic environments. In murine studies, the loss of LSAMP expression was associated with decreased sensitivity to amphetamine, increased sensitivity to benzodiazepines, increased hyperactivity in new environments, abnormal social behavior, decreased aggressive behavior, and decreased anxiety. Findings have suggested that LSAMP plays a role in attuning serotonergic activity as well as GABA activity. Given its importance to limbic system development, LSAMP has also been studied in the context of suicide. In malignancies, LSAMP may play a significant role as a putative tumor suppressor, the loss of which leads to more aggressive phenotypes and mortality from metastatic disease. Loss of the LSAMP gene facilitates epithelial-mesenchymal transition, or EMT, where epithelial cells lose adhesion and gain the motile properties associated with mesenchymal cells. Additionally, LSAMP and the function of the RTK pathway have been implicated in tumorigenesis through the modulation of RTK expression in cell membranes and the activation of second messenger pathways and β-catenin. Summary: Beyond its many roles in the limbic system, LSAMP functions as a putative tumor suppressor protein. Loss of the LSAMP gene is thought to facilitate epithelial-mesenchymal transition, or EMT, where cells lose adhesion and migrate to distant organs. LSAMP's role in modulating RTK activity and downstream ERK and Akt pathways adds to a large body of data investigating RTK expression in oncogenesis. The characteristics of LSAMP defects and their association with aggressive and metastatic disease are evident in reports on clear cell renal cell carcinoma, prostatic adenocarcinoma, lung adenocarcinoma, osteosarcoma, neuroblastoma, acute myeloid leukemia, and epithelial ovarian cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes

Author

Kohaar, Indu, Zhang, Xijun, Tan, Shyh-Han, Nousome, Darryl, Babcock, Kevin, Ravindranath, Lakshmi, Sukumar, Gauthaman, Mcgrath-Martinez, Elisa, Rosenberger, John, Alba, Camille, Ali, Amina, Young, Denise, Chen, Yongmei, Cullen, Jennifer, Rosner, Inger L., Sesterhenn, Isabell A., Dobi, Albert, Chesnut, Gregory, Turner, Clesson, Dalgard, Clifton, Wilkerson, Matthew D., Pollard, Harvey B., Srivastava, Shiv, and Petrovics, Gyorgy

Published
2022
Full Text
View/download PDF

14. Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry

Author

Conti, David V, Wang, Kan, Sheng, Xin, Bensen, Jeannette T, Hazelett, Dennis J, Cook, Michael B, Ingles, Sue A, Kittles, Rick A, Strom, Sara S, Rybicki, Benjamin A, Nemesure, Barbara, Isaacs, William B, Stanford, Janet L, Zheng, Wei, Sanderson, Maureen, John, Esther M, Park, Jong Y, Xu, Jianfeng, Stevens, Victoria L, Berndt, Sonja I, Huff, Chad D, Wang, Zhaoming, Yeboah, Edward D, Tettey, Yao, Biritwum, Richard B, Adjei, Andrew A, Tay, Evelyn, Truelove, Ann, Niwa, Shelley, Sellers, Thomas A, Yamoah, Kosj, Murphy, Adam B, Crawford, Dana C, Gapstur, Susan M, Bush, William S, Aldrich, Melinda C, Cussenot, Olivier, Petrovics, Gyorgy, Cullen, Jennifer, Neslund-Dudas, Christine, Stern, Mariana C, Jarai, Zsofia-Kote, Govindasami, Koveela, Chokkalingam, Anand P, Hsing, Ann W, Goodman, Phyllis J, Hoffmann, Thomas, Drake, Bettina F, Hu, Jennifer J, Clark, Peter E, Van Den Eeden, Stephen K, Blanchet, Pascal, Fowke, Jay H, Casey, Graham, Hennis, Anselm JM, Han, Ying, Lubwama, Alexander, Thompson, Ian M, Leach, Robin, Easton, Douglas F, Schumacher, Fredrick, Van den Berg, David J, Gundell, Susan M, Stram, Alex, Wan, Peggy, Xia, Lucy, Pooler, Loreall C, Mohler, James L, Fontham, Elizabeth TH, Smith, Gary J, Taylor, Jack A, Srivastava, Shiv, Eeles, Rosalind A, Carpten, John, Kibel, Adam S, Multigner, Luc, Parent, Marie-Elise, Menegaux, Florence, Cancel-Tassin, Geraldine, Klein, Eric A, Brureau, Laurent, Stram, Daniel O, Watya, Stephen, Chanock, Stephen J, Witte, John S, Blot, William J, Henderson, Brian E, and Haiman, Christopher A

Subjects
Aging, Human Genome, Cancer, Prevention, Prostate Cancer, Biotechnology, Clinical Research, Genetics, Urologic Diseases, 2.1 Biological and endogenous factors, Aetiology, Blacks, Case-Control Studies, Checkpoint Kinase 2, Chromosomes, Human, Pair 13, Chromosomes, Human, Pair 22, Gene Frequency, Genetic Loci, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Insulin Receptor Substrate Proteins, Male, Polymorphism, Single Nucleotide, Prostatic Neoplasms, PRACTICAL/ELLIPSE Consortium, Black People, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Prostate cancer incidence is 1.6-fold higher in African Americans than in other populations. The risk factors that drive this disparity are unknown and potentially consist of social, environmental, and genetic influences. To investigate the genetic basis of prostate cancer in men of African ancestry, we performed a genome-wide association meta-analysis using two-sided statistical tests in 10 202 case subjects and 10 810 control subjects. We identified novel signals on chromosomes 13q34 and 22q12, with the risk-associated alleles found only in men of African ancestry (13q34: rs75823044, risk allele frequency = 2.2%, odds ratio [OR] = 1.55, 95% confidence interval [CI] = 1.37 to 1.76, P = 6.10 × 10-12; 22q12.1: rs78554043, risk allele frequency = 1.5%, OR = 1.62, 95% CI = 1.39 to 1.89, P = 7.50 × 10-10). At 13q34, the signal is located 5' of the gene IRS2 and 3' of a long noncoding RNA, while at 22q12 the candidate functional allele is a missense variant in the CHEK2 gene. These findings provide further support for the role of ancestry-specific germline variation in contributing to population differences in prostate cancer risk.

Published
2017

17. Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression without inducing homologous recombination deficiency

Author

Szallasi, Zoltan, primary, Diossy, Miklos, additional, Tisza, Viktoria, additional, Li, Hua, additional, Sahgal, Pranshu, additional, Zhou, Jia, additional, Sztupinszki, Zsofia, additional, Young, Denise, additional, Nuosome, Darryl, additional, Kuo, Claire, additional, Jiang, Jiji, additional, Chen, Yongmei, additional, Ebner, Reinhard, additional, Sesterhenn, Isabell, additional, Moncur, Joel, additional, Chesnut, Gregory, additional, Petrovics, Gyorgy, additional, T.Klus, Gregory, additional, Valcz, Gábor, additional, Nuzzo, Pier, additional, Ribli, Dezso, additional, Börcsök, Judit, additional, Prósz, Aurél, additional, Krzystanek, Marcin, additional, Ried, Thomas, additional, Szüts, Dávid, additional, Rizwan, Kinza, additional, Kaochar, Salma, additional, Pathania, Shailja, additional, D'Andrea, Alan, additional, Csabai, István, additional, Srivast, Shib, additional, Freedman, Matthew, additional, Dobi, Albert, additional, and Spisak, Sandor, additional

Published
2024
Full Text
View/download PDF

18. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

Author

Conti, David V., Darst, Burcu F., Moss, Lilit C., Saunders, Edward J., Sheng, Xin, Chou, Alisha, Schumacher, Fredrick R., Olama, Ali Amin Al, Benlloch, Sara, Dadaev, Tokhir, Brook, Mark N., Sahimi, Ali, Hoffmann, Thomas J., Takahashi, Atushi, Matsuda, Koichi, Momozawa, Yukihide, Fujita, Masashi, Muir, Kenneth, Lophatananon, Artitaya, Wan, Peggy, Le Marchand, Loic, Wilkens, Lynne R., Stevens, Victoria L., Gapstur, Susan M., Carter, Brian D., Schleutker, Johanna, Tammela, Teuvo L. J., Sipeky, Csilla, Auvinen, Anssi, Giles, Graham G., Southey, Melissa C., MacInnis, Robert J., Cybulski, Cezary, Wokołorczyk, Dominika, Lubiński, Jan, Neal, David E., Donovan, Jenny L., Hamdy, Freddie C., Martin, Richard M., Nordestgaard, Børge G., Nielsen, Sune F., Weischer, Maren, Bojesen, Stig E., Røder, Martin Andreas, Iversen, Peter, Batra, Jyotsna, Chambers, Suzanne, Moya, Leire, Horvath, Lisa, Clements, Judith A., Tilley, Wayne, Risbridger, Gail P., Gronberg, Henrik, Aly, Markus, Szulkin, Robert, Eklund, Martin, Nordström, Tobias, Pashayan, Nora, Dunning, Alison M., Ghoussaini, Maya, Travis, Ruth C., Key, Tim J., Riboli, Elio, Park, Jong Y., Sellers, Thomas A., Lin, Hui-Yi, Albanes, Demetrius, Weinstein, Stephanie J., Mucci, Lorelei A., Giovannucci, Edward, Lindstrom, Sara, Kraft, Peter, Hunter, David J., Penney, Kathryn L., Turman, Constance, Tangen, Catherine M., Goodman, Phyllis J., Thompson, Jr., Ian M., Hamilton, Robert J., Fleshner, Neil E., Finelli, Antonio, Parent, Marie-Élise, Stanford, Janet L., Ostrander, Elaine A., Geybels, Milan S., Koutros, Stella, Freeman, Laura E. Beane, Stampfer, Meir, Wolk, Alicja, Håkansson, Niclas, Andriole, Gerald L., Hoover, Robert N., Machiela, Mitchell J., Sørensen, Karina Dalsgaard, Borre, Michael, Blot, William J., Zheng, Wei, Yeboah, Edward D., Mensah, James E., Lu, Yong-Jie, Zhang, Hong-Wei, Feng, Ninghan, Mao, Xueying, Wu, Yudong, Zhao, Shan-Chao, Sun, Zan, Thibodeau, Stephen N., McDonnell, Shannon K., Schaid, Daniel J., West, Catharine M. L., Burnet, Neil, Barnett, Gill, Maier, Christiane, Schnoeller, Thomas, Luedeke, Manuel, Kibel, Adam S., Drake, Bettina F., Cussenot, Olivier, Cancel-Tassin, Géraldine, Menegaux, Florence, Truong, Thérèse, Koudou, Yves Akoli, John, Esther M., Grindedal, Eli Marie, Maehle, Lovise, Khaw, Kay-Tee, Ingles, Sue A., Stern, Mariana C., Vega, Ana, Gómez-Caamaño, Antonio, Fachal, Laura, Rosenstein, Barry S., Kerns, Sarah L., Ostrer, Harry, Teixeira, Manuel R., Paulo, Paula, Brandão, Andreia, Watya, Stephen, Lubwama, Alexander, Bensen, Jeannette T., Fontham, Elizabeth T. H., Mohler, James, Taylor, Jack A., Kogevinas, Manolis, Llorca, Javier, Castaño-Vinyals, Gemma, Cannon-Albright, Lisa, Teerlink, Craig C., Huff, Chad D., Strom, Sara S., Multigner, Luc, Blanchet, Pascal, Brureau, Laurent, Kaneva, Radka, Slavov, Chavdar, Mitev, Vanio, Leach, Robin J., Weaver, Brandi, Brenner, Hermann, Cuk, Katarina, Holleczek, Bernd, Saum, Kai-Uwe, Klein, Eric A., Hsing, Ann W., Kittles, Rick A., Murphy, Adam B., Logothetis, Christopher J., Kim, Jeri, Neuhausen, Susan L., Steele, Linda, Ding, Yuan Chun, Isaacs, William B., Nemesure, Barbara, Hennis, Anselm J. M., Carpten, John, Pandha, Hardev, Michael, Agnieszka, De Ruyck, Kim, De Meerleer, Gert, Ost, Piet, Xu, Jianfeng, Razack, Azad, Lim, Jasmine, Teo, Soo-Hwang, Newcomb, Lisa F., Lin, Daniel W., Fowke, Jay H., Neslund-Dudas, Christine, Rybicki, Benjamin A., Gamulin, Marija, Lessel, Davor, Kulis, Tomislav, Usmani, Nawaid, Singhal, Sandeep, Parliament, Matthew, Claessens, Frank, Joniau, Steven, Van den Broeck, Thomas, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Martinez, Maria Elena, Larkin, Samantha, Townsend, Paul A., Aukim-Hastie, Claire, Bush, William S., Aldrich, Melinda C., Crawford, Dana C., Srivastava, Shiv, Cullen, Jennifer C., Petrovics, Gyorgy, Casey, Graham, Roobol, Monique J., Jenster, Guido, van Schaik, Ron H. N., Hu, Jennifer J., Sanderson, Maureen, Varma, Rohit, McKean-Cowdin, Roberta, Torres, Mina, Mancuso, Nicholas, Berndt, Sonja I., Van Den Eeden, Stephen K., Easton, Douglas F., Chanock, Stephen J., Cook, Michael B., Wiklund, Fredrik, Nakagawa, Hidewaki, Witte, John S., Eeles, Rosalind A., Kote-Jarai, Zsofia, and Haiman, Christopher A.

Published
2021
Full Text
View/download PDF

19. A long noncoding RNA connects c-Myc to tumor metabolism

Author

Hung, Chiu-Lien, Wang, Ling-Yu, Yu, Yen-Ling, Chen, Hong-Wu, Srivastava, Shiv, Petrovics, Gyorgy, and Kung, Hsing-Jien

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biological Sciences, Cancer, Genetics, Urologic Diseases, Prostate Cancer, Biotechnology, 1.1 Normal biological development and functioning, 2.1 Biological and endogenous factors, Aerobiosis, Cell Line, Tumor, Glycolysis, HEK293 Cells, Humans, Male, NADP, Pentose Phosphate Pathway, Promoter Regions, Genetic, Prostatic Neoplasms, Protein Structure, Tertiary, Proto-Oncogene Proteins c-myc, RNA, Long Noncoding, RNA, Neoplasm, Receptors, Androgen, lncRNA, tumor metabolism, c-Myc coactivator, prostate cancer
Abstract

Long noncoding RNAs (lncRNAs) have been implicated in a variety of physiological and pathological processes, including cancer. In prostate cancer, prostate cancer gene expression marker 1 (PCGEM1) is an androgen-induced prostate-specific lncRNA whose overexpression is highly associated with prostate tumors. PCGEM1's tumorigenic potential has been recently shown to be in part due to its ability to activate androgen receptor (AR). Here, we report a novel function of PCGEM1 that provides growth advantages for cancer cells by regulating tumor metabolism via c-Myc activation. PCGEM1 promotes glucose uptake for aerobic glycolysis, coupling with the pentose phosphate shunt to facilitate biosynthesis of nucleotide and lipid, and generates NADPH for redox homeostasis. We show that PCGEM1 regulates metabolism at a transcriptional level that affects multiple metabolic pathways, including glucose and glutamine metabolism, the pentose phosphate pathway, nucleotide and fatty acid biosynthesis, and the tricarboxylic acid cycle. The PCGEM1-mediated gene regulation takes place in part through AR activation, but predominantly through c-Myc activation, regardless of hormone or AR status. Significantly, PCGEM1 binds directly to target promoters, physically interacts with c-Myc, promotes chromatin recruitment of c-Myc, and enhances its transactivation activity. We also identified a c-Myc binding domain on PCGEM1 that contributes to the PCGEM1-dependent c-Myc activation and target induction. Together, our data uncover PCGEM1 as a key transcriptional regulator of central metabolic pathways in prostate cancer cells. By being a coactivator for both c-Myc and AR, PCGEM1 reprograms the androgen network and the central metabolism in a tumor-specific way, making it a promising target for therapeutic intervention.

Published
2014

21. Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort

Author

Cullen, Jennifer, Young, Denise, Chen, Yongmei, Degon, Michael, Farrell, James, Sedarsky, Jason, Baptiste, Wagner, Rosen, Philip, Tolstikov, Vladimir, Kiebish, Michael, Kagan, Jacob, Srivastava, Sudhir, Kuo, Huai-Ching, Moncur, Joel T., Rosner, Inger L., Narain, Niven, Akmaev, Viatcheslav, Petrovics, Gyorgy, Dobi, Albert, McLeod, David G., Srivastava, Shiv, and Sesterhenn, Isabell A.

Published
2018
Full Text
View/download PDF

22. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population

Author

Petrovics, Gyorgy, Price, Douglas K., Lou, Hong, Chen, Yongmei, Garland, Lisa, Bass, Sara, Jones, Kristine, Kohaar, Indu, Ali, Amina, Ravindranath, Lakshmi, Young, Denise, Cullen, Jennifer, Dorsey, Tiffany H., Sesterhenn, Isabell A., Brassell, Stephen A., Rosner, Inger L., Ross, Doug, Dahut, William, Ambs, Stefan, Figg, William Douglas, Srivastava, Shiv, and Dean, Michael

Published
2019
Full Text
View/download PDF

23. PCGEM1, a Prostate-Specific Gene, Is Overexpressed in Prostate Cancer

Author

Srikantan, Vasantha, Zou, Zhiqiang, Petrovics, Gyorgy, Xu, Linda, Augustus, Meena, Davis, Leland, Livezey, Jeffrey R., Connell, Theresa, Sesterhenn, Isabell A., Yoshino, Kiyoshi, Buzard, Gregory S., Mostofi, F. K., McLeod, David G., Moul, Judd W., and Srivastava, Shiv

Published
2000

24. Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry

Author

Darst, Burcu F., primary, Shen, Jiayi, additional, Madduri, Ravi K., additional, Rodriguez, Alexis A., additional, Xiao, Yukai, additional, Sheng, Xin, additional, Saunders, Edward J., additional, Dadaev, Tokhir, additional, Brook, Mark N., additional, Hoffmann, Thomas J., additional, Muir, Kenneth, additional, Wan, Peggy, additional, Le Marchand, Loic, additional, Wilkens, Lynne, additional, Wang, Ying, additional, Schleutker, Johanna, additional, MacInnis, Robert J., additional, Cybulski, Cezary, additional, Neal, David E., additional, Nordestgaard, Børge G., additional, Nielsen, Sune F., additional, Batra, Jyotsna, additional, Clements, Judith A., additional, Cancer BioResource, Australian Prostate, additional, Grönberg, Henrik, additional, Pashayan, Nora, additional, Travis, Ruth C., additional, Park, Jong Y., additional, Albanes, Demetrius, additional, Weinstein, Stephanie, additional, Mucci, Lorelei A., additional, Hunter, David J., additional, Penney, Kathryn L., additional, Tangen, Catherine M., additional, Hamilton, Robert J., additional, Parent, Marie-Élise, additional, Stanford, Janet L., additional, Koutros, Stella, additional, Wolk, Alicja, additional, Sørensen, Karina D., additional, Blot, William J., additional, Yeboah, Edward D., additional, Mensah, James E., additional, Lu, Yong-Jie, additional, Schaid, Daniel J., additional, Thibodeau, Stephen N., additional, West, Catharine M., additional, Maier, Christiane, additional, Kibel, Adam S., additional, Cancel-Tassin, Géraldine, additional, Menegaux, Florence, additional, John, Esther M., additional, Grindedal, Eli Marie, additional, Khaw, Kay-Tee, additional, Ingles, Sue A., additional, Vega, Ana, additional, Rosenstein, Barry S., additional, Teixeira, Manuel R., additional, Kogevinas, Manolis, additional, Cannon-Albright, Lisa, additional, Huff, Chad, additional, Multigner, Luc, additional, Kaneva, Radka, additional, Leach, Robin J., additional, Brenner, Hermann, additional, Hsing, Ann W., additional, Kittles, Rick A., additional, Murphy, Adam B., additional, Logothetis, Christopher J., additional, Neuhausen, Susan L., additional, Isaacs, William B., additional, Nemesure, Barbara, additional, Hennis, Anselm J., additional, Carpten, John, additional, Pandha, Hardev, additional, De Ruyck, Kim, additional, Xu, Jianfeng, additional, Razack, Azad, additional, Teo, Soo-Hwang, additional, Newcomb, Lisa F., additional, Fowke, Jay H., additional, Neslund-Dudas, Christine, additional, Rybicki, Benjamin A., additional, Gamulin, Marija, additional, Usmani, Nawaid, additional, Claessens, Frank, additional, Gago-Dominguez, Manuela, additional, Castelao, Jose Esteban, additional, Townsend, Paul A., additional, Crawford, Dana C., additional, Petrovics, Gyorgy, additional, Casey, Graham, additional, Roobol, Monique J., additional, Hu, Jennifer F., additional, Berndt, Sonja I., additional, Van Den Eeden, Stephen K., additional, Easton, Douglas F., additional, Chanock, Stephen J., additional, Cook, Michael B., additional, Wiklund, Fredrik, additional, Witte, John S., additional, Eeles, Rosalind A., additional, Kote-Jarai, Zsofia, additional, Watya, Stephen, additional, Gaziano, John M., additional, Justice, Amy C., additional, Conti, David V., additional, and Haiman, Christopher A., additional

Published
2023
Full Text
View/download PDF

26. Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry

Author

Darst, Burcu F., Shen, Jiayi, Madduri, Ravi K., Rodriguez, Alexis A., Xiao, Yukai, Sheng, Xin, Saunders, Edward J., Dadaev, Tokhir, Brook, Mark N., Hoffmann, Thomas J., Muir, Kenneth, Wan, Peggy, Marchand, Loic Le, Wilkens, Lynne, Wang, Ying, Schleutker, Johanna, MacInnis, Robert J., Cybulski, Cezary, Neal, David E., G. Nordestgaard, Børge, Nielsen, Sune F., Batra, Jyotsna, Clements, Judith A., Grönberg, Henrik, Pashayan, Nora, Travis, Ruth C., Park, Jong Y., Albanes, Demetrius, Weinstein, Stephanie, Mucci, Lorelei A., Hunter, David J., Penney, Kathryn L., Tangen, Catherine M., Hamilton, Robert J., Parent, Marie-Élise, Stanford, Janet L., Koutros, Stella, Wolk, Alicja, Sørensen, Karina D., Blot, William J., Yeboah, Edward D., Mensah, James E., Lu, Yong-Jie, Schaid, Daniel J., Thibodeau, Stephen N., West, Catharine M., Maier, Christiane, Kibel, Adam S., Cancel-Tassin, Géraldine, Menegaux, Florence, John, Esther M., Grindedal, Eli Marie, Khaw, Kay-Tee, Ingles, Sue A., Vega, Ana, Rosenstein, Barry S., Teixeira, Manuel R., Kogevinas, Manolis, Cannon-Albright, Lisa, Huff, Chad, Multigner, Luc, Kaneva, Radka, Leach, Robin J., Brenner, Hermann, Hsing, Ann W., Kittles, Rick A., Murphy, Adam B., Logothetis, Christopher J., Neuhausen, Susan L., Isaacs, William B., Nemesure, Barbara, Hennis, Anselm J., Carpten, John, Pandha, Hardev, De Ruyck, Kim, Xu, Jianfeng, Razack, Azad, Teo, Soo-Hwang, Newcomb, Lisa F., Fowke, Jay H., Neslund-Dudas, Christine, Rybicki, Benjamin A., Gamulin, Marija, Usmani, Nawaid, Claessens, Frank, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Townsend, Paul A., Crawford, Dana C., Petrovics, Gyorgy, Casey, Graham, Roobol, Monique J., Hu, Jennifer F., Berndt, Sonja I., Van Den Eeden, Stephen K., Easton, Douglas F., Chanock, Stephen J., Cook, Michael B., Wiklund, Fredrik, Witte, John S., Eeles, Rosalind A., Kote-Jarai, Zsofia, Watya, Stephen, Gaziano, John M., Justice, Amy C., Conti, David V., and Haiman, Christopher A.

Subjects
Article
Abstract

Genome-wide polygenic risk scores (GW-PRS) have been reported to have better predictive ability than PRS based on genome-wide significance thresholds across numerous traits. We compared the predictive ability of several GW-PRS approaches to a recently developed PRS of 269 established prostate cancer risk variants from multi-ancestry GWAS and fine-mapping studies (PRS (269) ). GW-PRS models were trained using a large and diverse prostate cancer GWAS of 107,247 cases and 127,006 controls used to develop the multi-ancestry PRS (269) . Resulting models were independently tested in 1,586 cases and 1,047 controls of African ancestry from the California/Uganda Study and 8,046 cases and 191,825 controls of European ancestry from the UK Biobank and further validated in 13,643 cases and 210,214 controls of European ancestry and 6,353 cases and 53,362 controls of African ancestry from the Million Veteran Program. In the testing data, the best performing GW-PRS approach had AUCs of 0.656 (95% CI=0.635-0.677) in African and 0.844 (95% CI=0.840-0.848) in European ancestry men and corresponding prostate cancer OR of 1.83 (95% CI=1.67-2.00) and 2.19 (95% CI=2.14-2.25), respectively, for each SD unit increase in the GW-PRS. However, compared to the GW-PRS, in African and European ancestry men, the PRS (269) had larger or similar AUCs (AUC=0.679, 95% CI=0.659-0.700 and AUC=0.845, 95% CI=0.841-0.849, respectively) and comparable prostate cancer OR (OR=2.05, 95% CI=1.87-2.26 and OR=2.21, 95% CI=2.16-2.26, respectively). Findings were similar in the validation data. This investigation suggests that current GW-PRS approaches may not improve the ability to predict prostate cancer risk compared to the multi-ancestry PRS (269) constructed with fine-mapping.

Published
2023

27. Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer

Author

Kiebish, Michael A., Cullen, Jennifer, Mishra, Prachi, Ali, Amina, Milliman, Eric, Rodrigues, Leonardo O., Chen, Emily Y., Tolstikov, Vladimir, Zhang, Lixia, Panagopoulos, Kiki, Shah, Punit, Chen, Yongmei, Petrovics, Gyorgy, Rosner, Inger L., Sesterhenn, Isabell A., McLeod, David G., Granger, Elder, Sarangarajan, Rangaprasad, Akmaev, Viatcheslav, Srinivasan, Alagarsamy, Srivastava, Shiv, Narain, Niven R., and Dobi, Albert

Published
2020
Full Text
View/download PDF

28. Clinical Biofluid Assays for Prostate Cancer.

Author

Borbiev, Talaibek, Kohaar, Indu, and Petrovics, Gyorgy

Subjects
SERODIAGNOSIS, EARLY detection of cancer, MICRORNA, DNA methylation, PROSTATE-specific antigen, BODY fluid examination, BIOLOGICAL assay, BLOOD testing, URINALYSIS, PROSTATE tumors
Abstract

Simple Summary: Prostate cancer (PCa) is the most frequent malignancy, and the second leading cause of cancer-related death, in men in the United States. PCa detection has been largely determined by the widely used prostate-specific antigen (PSA) blood test, followed by biopsy for a definitive diagnosis. Over the past years, more refined and more specific blood-based assays, as well as urine-based PCa tests, have driven remarkable progress in PCa detection and prognosis. Urine-based "liquid biopsies" provide minimally invasive, or non-invasive, options for the early detection and risk stratification of PCa. This mini review highlights current advancements and future perspectives. This mini review summarizes the currently available clinical biofluid assays for PCa. The second most prevalent cancer worldwide is PCa. PCa is a heterogeneous disease, with a large percentage of prostate tumors being indolent, and with a relatively slow metastatic potential. However, due to the high case numbers, the absolute number of PCa-related deaths is still high. In fact, it causes the second highest number of cancer deaths in American men. As a first step for the diagnosis of PCa, the PSA test has been widely used. However, it has low specificity, which results in a high number of false positives leading to overdiagnosis and overtreatment. Newer derivatives of the original PSA test, including the Food and Drug Administration (FDA)-approved 4K (four kallikreins) and the PHI (Prostate Health Index) blood tests, have higher specificities. Tissue-based PCa tests are problematic as biopsies are invasive and have limited accuracy due to prostate tumor heterogeneity. Liquid biopsies offer a minimally or non-invasive choice for the patients, while providing a more representative reflection of the spatial heterogeneity in the prostate. In addition to the abovementioned blood-based tests, urine is a promising source of PCa biomarkers, offering a supplementary avenue for early detection and improved tumor classification. Four urine-based PCa tests are either FDA- or CLIA-approved: PCA3 (PROGENSA), ExoDX Prostate Intelliscore, MiPS, and SelectMDx. We will discuss these urine-based, as well as the blood-based, clinical PCa tests in more detail. We also briefly discuss a few promising biofluid marker candidates (DNA methylation, micro-RNAs) which are not in clinical application. As no single assay is perfect, we envision that a combination of biomarkers, together with imaging, will become the preferred practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Data from Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells

Author

Mohamed, Ahmed A., primary, Tan, Shyh-Han, primary, Xavier, Charles P., primary, Katta, Shilpa, primary, Huang, Wei, primary, Ravindranath, Lakshmi, primary, Jamal, Muhammad, primary, Li, Hua, primary, Srivastava, Meera, primary, Srivatsan, Eri S., primary, Sreenath, Taduru L., primary, McLeod, David G., primary, Srinivasan, Alagarsamy, primary, Petrovics, Gyorgy, primary, Dobi, Albert, primary, and Srivastava, Shiv, primary

Published
2023
Full Text
View/download PDF

31. Table S1, S2 from Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells

Author

Mohamed, Ahmed A., primary, Tan, Shyh-Han, primary, Xavier, Charles P., primary, Katta, Shilpa, primary, Huang, Wei, primary, Ravindranath, Lakshmi, primary, Jamal, Muhammad, primary, Li, Hua, primary, Srivastava, Meera, primary, Srivatsan, Eri S., primary, Sreenath, Taduru L., primary, McLeod, David G., primary, Srinivasan, Alagarsamy, primary, Petrovics, Gyorgy, primary, Dobi, Albert, primary, and Srivastava, Shiv, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 1 from ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer

Author

Griner, Nicholas B., primary, Young, Denise, primary, Chaudhary, Pankaj, primary, Mohamed, Ahmed A., primary, Huang, Wei, primary, Chen, Yongmei, primary, Sreenath, Taduru, primary, Dobi, Albert, primary, Petrovics, Gyorgy, primary, Vishwanatha, Jamboor K., primary, Sesterhenn, Isabell A., primary, Srivastava, Shiv, primary, and Tan, Shyh-Han, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figures S6- S12 from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth

Author

Mohamed, Ahmed A., primary, Xavier, Charles P., primary, Sukumar, Gauthaman, primary, Tan, Shyh-Han, primary, Ravindranath, Lakshmi, primary, Seraj, Nishat, primary, Kumar, Vineet, primary, Sreenath, Taduru, primary, McLeod, David G., primary, Petrovics, Gyorgy, primary, Rosner, Inger L., primary, Srivastava, Meera, primary, Strovel, Jeffrey, primary, Malhotra, Sanjay V., primary, LaRonde, Nicole A., primary, Dobi, Albert, primary, Dalgard, Clifton L., primary, and Srivastava, Shiv, primary

Published
2023
Full Text
View/download PDF

35. Data from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth

Author

Mohamed, Ahmed A., primary, Xavier, Charles P., primary, Sukumar, Gauthaman, primary, Tan, Shyh-Han, primary, Ravindranath, Lakshmi, primary, Seraj, Nishat, primary, Kumar, Vineet, primary, Sreenath, Taduru, primary, McLeod, David G., primary, Petrovics, Gyorgy, primary, Rosner, Inger L., primary, Srivastava, Meera, primary, Strovel, Jeffrey, primary, Malhotra, Sanjay V., primary, LaRonde, Nicole A., primary, Dobi, Albert, primary, Dalgard, Clifton L., primary, and Srivastava, Shiv, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 7 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair

Author

Dal Pra, Alan, primary, Lalonde, Emilie, primary, Sykes, Jenna, primary, Warde, Fiona, primary, Ishkanian, Adrian, primary, Meng, Alice, primary, Maloff, Chad, primary, Srigley, John, primary, Joshua, Anthony M., primary, Petrovics, Gyorgy, primary, van der Kwast, Theodorus, primary, Evans, Andrew, primary, Milosevic, Michael, primary, Saad, Fred, primary, Collins, Colin, primary, Squire, Jeremy, primary, Lam, Wan, primary, Bismar, Tarek A., primary, Boutros, Paul C., primary, and Bristow, Robert G., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 3 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair

Author

Dal Pra, Alan, primary, Lalonde, Emilie, primary, Sykes, Jenna, primary, Warde, Fiona, primary, Ishkanian, Adrian, primary, Meng, Alice, primary, Maloff, Chad, primary, Srigley, John, primary, Joshua, Anthony M., primary, Petrovics, Gyorgy, primary, van der Kwast, Theodorus, primary, Evans, Andrew, primary, Milosevic, Michael, primary, Saad, Fred, primary, Collins, Colin, primary, Squire, Jeremy, primary, Lam, Wan, primary, Bismar, Tarek A., primary, Boutros, Paul C., primary, and Bristow, Robert G., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Tables S1-S4 from Higher Expression of the Androgen-Regulated Gene PSA/HK3 mRNA in Prostate Cancer Tissues Predicts Biochemical Recurrence-Free Survival

Author

Sterbis, Joseph R., primary, Gao, Chunling, primary, Furusato, Bungo, primary, Chen, Yongmei, primary, Shaheduzzaman, Syed, primary, Ravindranath, Lakshmi, primary, Osborn, David J., primary, Rosner, Inger L., primary, Dobi, Albert, primary, McLeod, David G., primary, Sesterhenn, Isabell A., primary, Srivastava, Shiv, primary, Cullen, Jennifer, primary, and Petrovics, Gyorgy, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Materials and Methods and References from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth

Author

Mohamed, Ahmed A., primary, Xavier, Charles P., primary, Sukumar, Gauthaman, primary, Tan, Shyh-Han, primary, Ravindranath, Lakshmi, primary, Seraj, Nishat, primary, Kumar, Vineet, primary, Sreenath, Taduru, primary, McLeod, David G., primary, Petrovics, Gyorgy, primary, Rosner, Inger L., primary, Srivastava, Meera, primary, Strovel, Jeffrey, primary, Malhotra, Sanjay V., primary, LaRonde, Nicole A., primary, Dobi, Albert, primary, Dalgard, Clifton L., primary, and Srivastava, Shiv, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 1 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair

Author

Dal Pra, Alan, primary, Lalonde, Emilie, primary, Sykes, Jenna, primary, Warde, Fiona, primary, Ishkanian, Adrian, primary, Meng, Alice, primary, Maloff, Chad, primary, Srigley, John, primary, Joshua, Anthony M., primary, Petrovics, Gyorgy, primary, van der Kwast, Theodorus, primary, Evans, Andrew, primary, Milosevic, Michael, primary, Saad, Fred, primary, Collins, Colin, primary, Squire, Jeremy, primary, Lam, Wan, primary, Bismar, Tarek A., primary, Boutros, Paul C., primary, and Bristow, Robert G., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Tables S1 and S2 from Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth

Author

Mohamed, Ahmed A., primary, Xavier, Charles P., primary, Sukumar, Gauthaman, primary, Tan, Shyh-Han, primary, Ravindranath, Lakshmi, primary, Seraj, Nishat, primary, Kumar, Vineet, primary, Sreenath, Taduru, primary, McLeod, David G., primary, Petrovics, Gyorgy, primary, Rosner, Inger L., primary, Srivastava, Meera, primary, Strovel, Jeffrey, primary, Malhotra, Sanjay V., primary, LaRonde, Nicole A., primary, Dobi, Albert, primary, Dalgard, Clifton L., primary, and Srivastava, Shiv, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Tables 1-5, Supplementary Figures 1-4 from Prostate Cancer Risk Allele Specific for African Descent Associates with Pathologic Stage at Prostatectomy

Author

Whitman, Eric J., primary, Pomerantz, Mark, primary, Chen, Yongmei, primary, Chamberlin, Michael M., primary, Furusato, Bungo, primary, Gao, Chunling, primary, Ali, Amina, primary, Ravindranath, Lakshmi, primary, Dobi, Albert, primary, Sestrehenn, Isabell A., primary, McLeod, David G., primary, Srivastava, Shiv, primary, Freedman, Matthew, primary, and Petrovics, Gyorgy, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 5 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair

Author

Dal Pra, Alan, primary, Lalonde, Emilie, primary, Sykes, Jenna, primary, Warde, Fiona, primary, Ishkanian, Adrian, primary, Meng, Alice, primary, Maloff, Chad, primary, Srigley, John, primary, Joshua, Anthony M., primary, Petrovics, Gyorgy, primary, van der Kwast, Theodorus, primary, Evans, Andrew, primary, Milosevic, Michael, primary, Saad, Fred, primary, Collins, Colin, primary, Squire, Jeremy, primary, Lam, Wan, primary, Bismar, Tarek A., primary, Boutros, Paul C., primary, and Bristow, Robert G., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Data from Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer

Author

Hu, Ying, primary, Dobi, Albert, primary, Sreenath, Taduru, primary, Cook, Christopher, primary, Tadase, Atekelt Y., primary, Ravindranath, Lakshmi, primary, Cullen, Jennifer, primary, Furusato, Bungo, primary, Chen, Yongmei, primary, Thangapazham, Rajesh L., primary, Mohamed, Ahmed, primary, Sun, Chen, primary, Sesterhenn, Isabell A., primary, McLeod, David G., primary, Petrovics, Gyorgy, primary, and Srivastava, Shiv, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 6 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair

Author

Dal Pra, Alan, primary, Lalonde, Emilie, primary, Sykes, Jenna, primary, Warde, Fiona, primary, Ishkanian, Adrian, primary, Meng, Alice, primary, Maloff, Chad, primary, Srigley, John, primary, Joshua, Anthony M., primary, Petrovics, Gyorgy, primary, van der Kwast, Theodorus, primary, Evans, Andrew, primary, Milosevic, Michael, primary, Saad, Fred, primary, Collins, Colin, primary, Squire, Jeremy, primary, Lam, Wan, primary, Bismar, Tarek A., primary, Boutros, Paul C., primary, and Bristow, Robert G., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Material from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair

Author

Dal Pra, Alan, primary, Lalonde, Emilie, primary, Sykes, Jenna, primary, Warde, Fiona, primary, Ishkanian, Adrian, primary, Meng, Alice, primary, Maloff, Chad, primary, Srigley, John, primary, Joshua, Anthony M., primary, Petrovics, Gyorgy, primary, van der Kwast, Theodorus, primary, Evans, Andrew, primary, Milosevic, Michael, primary, Saad, Fred, primary, Collins, Colin, primary, Squire, Jeremy, primary, Lam, Wan, primary, Bismar, Tarek A., primary, Boutros, Paul C., primary, and Bristow, Robert G., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 2 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair

Author

Dal Pra, Alan, primary, Lalonde, Emilie, primary, Sykes, Jenna, primary, Warde, Fiona, primary, Ishkanian, Adrian, primary, Meng, Alice, primary, Maloff, Chad, primary, Srigley, John, primary, Joshua, Anthony M., primary, Petrovics, Gyorgy, primary, van der Kwast, Theodorus, primary, Evans, Andrew, primary, Milosevic, Michael, primary, Saad, Fred, primary, Collins, Colin, primary, Squire, Jeremy, primary, Lam, Wan, primary, Bismar, Tarek A., primary, Boutros, Paul C., primary, and Bristow, Robert G., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 4 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair

Author

Dal Pra, Alan, primary, Lalonde, Emilie, primary, Sykes, Jenna, primary, Warde, Fiona, primary, Ishkanian, Adrian, primary, Meng, Alice, primary, Maloff, Chad, primary, Srigley, John, primary, Joshua, Anthony M., primary, Petrovics, Gyorgy, primary, van der Kwast, Theodorus, primary, Evans, Andrew, primary, Milosevic, Michael, primary, Saad, Fred, primary, Collins, Colin, primary, Squire, Jeremy, primary, Lam, Wan, primary, Bismar, Tarek A., primary, Boutros, Paul C., primary, and Bristow, Robert G., primary

Published
2023
Full Text
View/download PDF

49. Data from Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC Expression

Author

Pomerantz, Mark M., primary, Beckwith, Christine A., primary, Regan, Meredith M., primary, Wyman, Stacia K., primary, Petrovics, Gyorgy, primary, Chen, Yongmei, primary, Hawksworth, Dorota J., primary, Schumacher, Fredrick R., primary, Mucci, Lorelei, primary, Penney, Kathryn L., primary, Stampfer, Meir J., primary, Chan, Jennifer A., primary, Ardlie, Kristin G., primary, Fritz, Brian R., primary, Parkin, Rachael K., primary, Lin, Daniel W., primary, Dyke, Michelle, primary, Herman, Paula, primary, Lee, Steve, primary, Oh, William K., primary, Kantoff, Philip W., primary, Tewari, Muneesh, primary, McLeod, David G., primary, Srivastava, Shiv, primary, and Freedman, Matthew L., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure 1 from Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC Expression

Author

Pomerantz, Mark M., primary, Beckwith, Christine A., primary, Regan, Meredith M., primary, Wyman, Stacia K., primary, Petrovics, Gyorgy, primary, Chen, Yongmei, primary, Hawksworth, Dorota J., primary, Schumacher, Fredrick R., primary, Mucci, Lorelei, primary, Penney, Kathryn L., primary, Stampfer, Meir J., primary, Chan, Jennifer A., primary, Ardlie, Kristin G., primary, Fritz, Brian R., primary, Parkin, Rachael K., primary, Lin, Daniel W., primary, Dyke, Michelle, primary, Herman, Paula, primary, Lee, Steve, primary, Oh, William K., primary, Kantoff, Philip W., primary, Tewari, Muneesh, primary, McLeod, David G., primary, Srivastava, Shiv, primary, and Freedman, Matthew L., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results